INTRODUCTION {#s1}
============

Approximately 50% of patients with primary colorectal cancer will develop liver metastases during their disease course \[[@R1]\]. Hepatic resection remains the only potentially curative treatment option for patients with colorectal liver metastasis (CRLM). While 5-year survival rates can be as high as 50--58%, patient prognoses can vary considerably \[[@R2], [@R3]\].

Criteria used to select CRLM patients for hepatic resection are based largely on clinical and radiologic parameters, such as tumor size and number, and response to preoperative chemotherapy, that attempt to predict prognosis post-resection \[[@R4]--[@R6]\]. Preoperative chemotherapy can shrink metastases and increase their resectability, and may also help select patients most likely to benefit from surgery \[[@R7], [@R8]\]. However, the prognostic landscape for predicting long-term outcomes in patients undergoing CRLM resection is changing \[[@R9]\]. Many prognostic models now rely on clinicopathological factors and tumor-specific molecular markers. Combining multiple factors within a single scoring system would better aid clinical decision-making. Thus, the present study investigated various tumor-related factors to develop a scoring system to predict CRLM patient survival following hepatic resection.

RESULTS {#s2}
=======

This study analyzed 300 patients who received preoperative chemotherapy and underwent hepatic resection to treat CRLM between January 2006 and December 2016 (Table [1](#T1){ref-type="table"}). No patients died from postoperative complications within 90 days of surgery, and all were eligible for the final analysis. Primary tumor resection was performed before hepatic resection in 173 patients (57.7%), during in 77 (25.7%) and after in 44 (16.6%). Liver metastasis was diagnosed synchronously in 265 patients (88.3%). Concomitant extrahepatic disease was present in 54 patients (18%). Conversion and neoadjvuant chemotherapy features are summarized in Table [2](#T2){ref-type="table"}. Preoperative chemotherapy was administered to all patients with a median of four (range, 1--16) cycles. Major hepatic resection was performed in 135 patients (45.0%). 190 patients had a KRAS mutation, 155 had a Fong clinical risk score (CRS) \> 2, and 182 exhibited poor response to preoperative chemotherapy.

###### Demographic and clincial characteristics of study patients

  Variable                           No. of patients
  ---------------------------------- -----------------
  Patients demographics              
  Age (years)                        55 (21--82)
  Sex ration (M:F)                   196:104
  Primary T category                 
   T1--2                             50 (16.7%)
   T3--4                             250 (83.3%)
  Primary N category                 
   N0                                136 (45.3%)
   N1--2                             164 (54.7%)
  Primary tumor location             
   Colon                             128 (42.7%)
   Rectum                            172 (57.3%)
  Primary tumor                      
   Right                             53 (17.7%)
   Left                              247 (82.3%)
  Primary tumor resection            
   Before hepatectomy                179 (59.7%)
   During hepatectomy                77 (25.7%)
   After hepatectomy                 44 (14.6%)
  Timing of liver metastasis         
   Synchronous                       265 (88.3%)
   Metachronous                      35 (11.7%)
  Tumor no.                          3 (1--22)
  Tumor size (mm)                    25 (1--150)
  Localization of liver metastases   
   Unilobar                          135 (45.0%)
   Bilobar                           165 (55.0%)
  CEA level (ng/ml)                  7.11 (0.1--861)
  Concomitant extrahepatic disease   54 (18.0%)
  Pre-treatment                      
   Conversion                        65 (21.7%)
   Neoadjuvant                       235 (78.3%)

###### Details of preoperative chemotherapy and hepatic resection

  Variable                                No. of patients
  --------------------------------------- -----------------
  Chemotherapy before hepatic resection   
  No. of cycles                           4 (1--16)
  No. of lines                            
   First line                             237 (79.0%)
   Second line                            56 (18.7%)
   Third line                             7 (2.3%)
  Response to last-line chemotherapy      
   Complete                               3 (1.0%)
   Partial                                128 (42.7%)
   Stable disease                         141 (47.0%)
   Progressive disease                    28 (9.3%)
  Surgery details                         
   Operation time(min)                    221.7 ± 84.0
  Blood lose(ml)                          272.0 ± 99.0
   Hepatic resection                      
   Major resection                        135 (45.0%)
   Minor resection                        165 (55.0%)
  Margine status                          
   Positive                               58 (19.3%)
   Negative                               242 (80.7%)
  Complication                            
  Major(Clavien grade ≥ 3)                12 (4.0%)
  Minor(Clavien grade \< 3)               26 (8.7%)

Long-term outcomes {#s2_1}
------------------

Median follow-up time was 45 (range, 1--131) months, and no patients died during follow-up. Cumulative overall survival (OS) rates 1, 3, and 5 years after hepatic resection were 92.7%, 58.3%, and 45.8%, respectively. Cumulative disease-free survival (DFS) rates 1, 3, and 5 years after surgery were 44.7%, 28.6%, and 24.2% respectively, on an intention-to-treat basis (Figure [1](#F1){ref-type="fig"}).

![Kaplan-meier curve showing OS and DFS](oncotarget-08-79927-g001){#F1}

Univariate and multivariate analyses of factors associated with OS {#s2_2}
------------------------------------------------------------------

In univariate analyses, five variables, including KRAS mutation, Fong CRS \> 2, tumor number\>1, size \> 5 cm at diagnosis, and poor response to preoperative chemotherapy, were associated with decreased OS (*p \<* 0.050) (Table [3](#T3){ref-type="table"}). These variables were included in a subsequent multivariate Cox regression analysis, which identified three independent prognostic factors for OS: Fong CRS \> 2 (HR: 4.247; 95% CI: 1.758--8.260; *p* = 0.001), KRAS mutation (HR: 2.196; 95% CI: 1.372--3.515; *p \<* 0.001) and poor response to preoperative chemotherapy (HR: 2.054; 95% CI: 1.025--4.119; *p* = 0.042) (Table [3](#T3){ref-type="table"}).

###### Prognostic factors of overall survival after hepatectomy

  Analysis                                         n     5-year OS   HR      95% CI         *p* value
  ---------------------------------- ------------- ----- ----------- ------- -------------- -----------
  **Univaraite**                                                                            
  Age                                \> 60 y       94    40.7%       0.874   0.556--1.375   0.561
                                     ≤ 60          206   47.6%                              
  Sex                                Male          196   39.9%       1.215   0.773--1.911   0.399
                                     Female        104   56.4%                              
  Primary T category                 T1-T2         50    40.9%       0.849   0.494--1.459   0.554
                                     T3-T4         250   46.7%                              
  Primary N category                 N0            136   44.7%       1.079   0.711--1.638   0.721
                                     N1            164   45.6%                              
  Primary tumor location             Left          247   42.4%       1.325   0.735--2.368   0.349
                                     Right         53    42.0%                              
  Timing of liver metastasis         Synchronous   265   43.8%       1.497   0.748--2.995   0.255
                                     Metchronous   35    58.5%                              
  Tumor no. at diagnosis             *n =* 1       80    54.5%       1.686   1.012--2.809   0.045
                                     *n* \> 1      220   42.7%                              
  Tumor size at diagnosis            \> 50 mm      41    22.7%       2.414   1.518--3.863   0.000
                                     ≤ 50          259   53.2%                              
  Location of liver metastasis       Bilobar       165   43.9%       1.262   0.826--1.928   0.282
                                     Unilobar      135   46.8%                              
  CEA level(ng/ml)                   \> 200        15    46.4%       2.114   0.917--4.877   0.079
                                     ≤ 200         285   46.7%                              
  Concomitant extrahepatic disease   Yes           54    41.3%       1.408   0.896--2.281   0.164
                                     No            246   47.2%                              
  Major hepatectomy                  Yes           135   40.2%       1.436   0.947--2.177   0.089
                                     No            165   50.3%                              
  CRS                                ≤ 2           155   57.5%       2.427   1.575--3.740   0.000
                                     \> 2          145   32.6%                              
  KRAS status type                   Wild          190   53.6%       2.691   1.772--4.086   0.000
                                     Mutation      110   31.7%                              
  Worse chemotherapy response        Yes           182   33.8%       2.010   1.322--3.057   0.001
                                     No            118   51.8%                              
  Margin                             Positive      58    45.1%       1.029   0.491--2.156   0.939
                                     Negative      242   46.3%                              
  Pre-treatment                      Neo           235   48.2%       1.130   0.679--1.881   0.637
                                     Con           65    33.1%                              
  Primary tumor                      Rectum        172   50.1%       1.301   0.859--1.972   0.214
                                     Colon         128   39.9%                              
  Mjaor complications                Yes           12    42.8%       1.228   0.674--2.236   0.117
                                     No            288   47.6%                              
  **Multivaraite**                                                                          
  Tumor no. at diagnosis             *n* \> 1      220               2.588   0.787--8.511   0.117
  Tumor size at diagnosis            \> 50 mm      41                3.140   0.935--4.542   0.064
  CRS                                \> 2          155               4.247   1.758--8.260   0.001
  KRAS status                        Mutation      190               2.196   1.372--3.515   0.001
  Chemotherapy response              Worse         182               2.054   1.025--4.119   0.042

Tumor biology score {#s2_3}
-------------------

KRAS mutation, Fong CRS \> 2, and poor preoperative chemotherapy response were chosen as criteria for a tumor biology score (TBS) staging system. Each risk factor was assigned one point, and total score was compared with the clinical outcome of each patient after hepatic resection. Five-year OS rates for patients scoring TBS 0, 1, 2, and 3 were 63.7%, 49.6%, 33.3%, and 14.1%, respectively (Figure [2](#F2){ref-type="fig"}).

![Kaplan-meier curve showing overall survival of TBS system](oncotarget-08-79927-g002){#F2}

Prognostic predictive power {#s2_4}
---------------------------

Nine eligible studies satisfied our inclusion criteria, and patient demographic and clinicopathological data were extracted ([Supplementary Table 1](#SD2){ref-type="supplementary-material"}) \[[@R4], [@R5], [@R10]--[@R16]\]. The predictive powers of the Fong, Iwatsuki, Konopke, Nagashima, Nordlinger, Pawlik, Rees, Vauthey scores, and our TBS were 0.585 (95% CI: 0.520--0.549; *p =* 0.011), 0.513 (95% CI: 0.443--0.584; *p* = 0.710), 0.585 (95% CI: 0.474--0.696; *p* = 0.098), 0.509 (95% CI: 0.443--0.575; *p* = 0.788), 0.529 (95% CI: 0.464--0.594; *p* = 0.385), 0.524 (95% CI: 0.451--0.598; *p* = 0.506), 0.510 (95% CI: 0.440--0.581; *p* = 0.769), 0.615 (95% CI: 0.531--0.699; *p* = 0.043), and 0.642 (95% CI: 0.570--0.713; *p* = 0.036), respectively.

DISCUSSION {#s3}
==========

This study investigated several prognostic factors related to OS in patients with CRLM, and produced a rational tumor biology score system. Multivariate Cox regression analysis identified three variables, including KRAS mutation, Fong CRS \> 2, and poor preoperative chemotherapy response, as independent prognostic factors for CRLM patients who plan to undergo hepatic resection.

In selected patients with unresectable disease, conversion chemotherapy may allow for secondary resection and improved long-term survival \[[@R17]\]. Neoadjuvant chemotherapy has been also proposed for patients with resectable disease and negative prognostic factors to better select those who could benefit from liver surgery, and to avoid surgery in patients with rapidly progressing tumors \[[@R18]\]. RECIST was established to assess cytotoxic treatment effects in solid tumors, and CRLM response to preoperative chemotherapy has prognostic value \[[@R8]\]. Partial response suggests a better prognosis, while stable disease is likely due to tumor cell resistance. However, recent findings question the effectiveness of RECIST in colorectal cancer patients \[[@R19]\]. The conventional tumor size-based radiologic criteria of RECIST may be inadequate in assessing response to chemotherapy, especially in patients treated with a regimen including bevacizumab \[[@R20]\]. Lesions that are predominantly necrotic may not be ideal RECIST targets, because their attenuation closely mimics that of a treated lesion. In some instances, stable disease response may be inconsistent with improvement via RECIST criteria, but still associated with an optimal morphologic response \[[@R21]\]. More recently, investigators have proposed pathological and radiological responses to chemotherapy as alternative outcome endpoints for predicting survival after CRLM resection \[[@R21], [@R22]\]. However, pathological response can be assessed only after surgery, and survival was associated with radiological response primarily in patients receiving preoperative anti-vascular endothelial growth factor (VEGF) therapy \[[@R23], [@R24]\].

Several clinical risk scores (CRS) have been developed to predict tumor recurrence and survival after CRLM resection \[[@R4], [@R5]\]. The most validated and widely-used CRS was described by Fong, *et al.* in 1999 \[[@R4]\]. The Fong CRS identified five independent prognostic clinical variables predicting survival after CRLM surgery, and characterized two risk groups: patients with a high-risk profile have worse OS rates than low-risk patients. Although all CRLMs may be considered high risk, this CRS may explain the relative lack of systemic therapy efficacy when combined with surgery in the metastasized setting. Tomlinson, *et al.* demonstrated in CRLM surgery 10-year sur*vivo*rs that patients with a low Fong CRS had a cure rate of 21% versus 10% in patients with a high CRS \[[@R25]\]. In high CRS patients, perioperative chemotherapy was associated with a survival advantage, but was of no benefit in low CRS patients. Data suggests that patients with a low CRS have a favorable tumor biology \[[@R26]\]. However, large, single-institution studies have questioned the validity and clinical usefulness of risk scores \[[@R27], [@R28]\]. The prognostic significance of most of these factors was determined at a time when effective cytotoxic agents were not available. Consequently, although most of these factors are still routinely used, their utility as prognostic indicators in the era of modern chemotherapy is uncertain and should be reassessed.

While many prognostic models now rely on clinicopathological factors, molecular biomarkers are likely to replace traditional clinical and morphometric factors \[[@R9], [@R29]\]. KRAS mutations are associated with tumor cell migration and invasion via disruption of the actin cytoskeleton and regulation of integrin expression, among other mechanisms \[[@R30], [@R31]\]. The prognostic importance of activating KRAS mutations extends beyond predicting sensitivity to anti-EGFR monoclonal antibodies, and may reflect a more migratory and invasive tumor biology resulting in early and frequent recurrences after hepatic resection. Historically, survival predictions were based on primary tumor and metastases morphological characteristics. Factors associated with aggressive or advanced tumor biology, such as bilobar disease, multiple metastases, large metastases, and metastases in difficult locations, are also associated with technically complex cases.

In conclusion, our analysis revealed three important factors for predicting prognosis in CRLM patients undergoing surgery. Characterization of novel biomarkers in these patients will enhance our understanding of CRLM aggressiveness, assist in clinical decision-making, and help to identify new, more efficient therapies.

MATERIALS AND METHODS {#s4}
=====================

Patients {#s4_1}
--------

Between January 2006 and December 2016, 300 CRLM patients received preoperative chemotherapy and underwent hepatic resection at the Hepatopancreatobiliary Surgery Department I of Peking University Cancer Hospital. CRLM diagnoses were all confirmed by histopathology.

Preoperative management {#s4_2}
-----------------------

As a result of the long study period, response to chemotherapy was classified according to World Health Organization criteria, which are in agreement with the Response Evaluation Criteria in Solid Tumors (RECIST) \[[@R32]\]. Poor preoperative chemotherapy response was represented by progressive disease or stable disease with the target lesion increased in diameter by \< 30%. If the disease was not controlled with chemotherapy, systemic chemotherapy was restarted using another regimen. Response was then re-evaluated to assess the possibility of surgery. Response was based on the last-line preoperative chemotherapy before hepatic resection. Two radiologists reviewed all images from the 300 patients independently.

Surgical treatment {#s4_3}
------------------

The objective of surgery was to resect all detectable lesions with tumor-free margins. If obtaining a tumor-free margin was not possible due to contact with major vascular or biliary structures, resection was still indicated provided that all tumors could be resected macroscopically. All patients underwent hepatic resection with curative intent, and to achieve complete resection (R0) while preserving as much normal functional liver parenchyma (with adequate vascular inflow, outflow, and biliary drainage) as possible. Resection of three or more segments was considered a major hepatic resection. The normal liver parenchyma remnant volume was \> 30%. For chemotherapy liver injury patients, the remnant volume should be preserved at \> 40%. The presence of extrahepatic tumors was not considered a contraindication to hepatic resection if the lesions were limited and resectable. Extrahepatic disease identified in the abdominal cavity was resected at the same time as hepatic resection. For extrahepatic disease located outside the abdomen, resection was performed 2--3 months after hepatectomy if the disease remained controlled with interval chemotherapy.

Postoperative treatment {#s4_4}
-----------------------

Postoperative chemotherapy was recommended routinely, using the same protocol as that applied before surgery. Recurrence was treated surgically only when the overall strategy was considered potentially curative. All patients were followed up every three months for the first two years, with a physical examination, carcinoembryonic antigen (CEA) measurement, and abdominal ultrasonography. Every six months, patients underwent computed tomography scan of the abdominal/thoracic/pelvic region (enhanced MRI could replace CT). No patients died during follow-up.

Statistical analysis {#s4_5}
--------------------

Continuous variables were summarized as means and categorical variables were summarized as frequencies and percentages. Qualitative variable comparisons were performed using Pearson's chi-square test. Kaplan-Meier survival curves were calculated from the date of hepatic resection and differences were determined using a log-rank test. Clinicopathologic factors were analyzed using Cox's proportional hazard model to identify independent risk factors for overall survival. *p* \< 0.05 (two-sided) was considered significant. Statistical analyses were performed using SPSS 19.0 (SPSS, Inc., Chicago, IL, USA).

Comprehensive MEDLINE review {#s4_6}
----------------------------

We comprehensively searched the MEDLINE database using the following medical subject headings (MeSH): "colorectal liver metastases" or "colorectal metastasis" and "liver resection" or "hepatic resection" or "surgery". We also manually searched relevant references and review articles. Studies were included in our review if they (a) proposed a scoring system to predict CRLM survival outcome, (b) were published in English, and (c) were published between January 1990 and April 2017, to ensure comparability with our retrospective clinical study. Studies involving fewer than 50 patients were excluded. To compare staging systems as predictors of prognosis after hepatic resection, we used the concordance c-statistic (as the area under the receiver operating characteristic \[ROC\] curve). Prognostic system performance is related to homogeneity (small differences in survival among patients at the same stage within each system), discrimination ability (greater differences in survival among patients at different stages within each system), and monotonicity of gradients (survival of patients at earlier stages is longer than that of patients at more advanced stages within the same system).

SUPPLEMENTARY MATERIALS TABLES {#s5}
==============================
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